{"id":"influenza-vaccine-gsk2340272a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Systemic reactions (fever, myalgia, fatigue)"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an influenza vaccine candidate, GSK2340272A works by presenting influenza viral antigens to the immune system to generate protective antibody and T-cell responses. This approach aims to prevent infection or reduce severity of influenza illness by priming the adaptive immune system to recognize and respond to circulating influenza strains. The specific formulation and adjuvant strategy of GSK2340272A are proprietary to GlaxoSmithKline's vaccine development program.","oneSentence":"GSK2340272A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:03.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT00968539","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":130},{"nctId":"NCT00989287","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-07","conditions":"Influenza","enrollment":131},{"nctId":"NCT00972517","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-29","conditions":"Influenza","enrollment":245},{"nctId":"NCT00968526","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":240},{"nctId":"NCT00975884","phase":"PHASE3","title":"Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-14","conditions":"Influenza","enrollment":312},{"nctId":"NCT00971321","phase":"PHASE2","title":"Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT00992511","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-14","conditions":"Influenza","enrollment":300},{"nctId":"NCT00989612","phase":"PHASE2","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT00951041","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-11","conditions":"Influenza","enrollment":130},{"nctId":"NCT01014091","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT00968890","phase":"PHASE2","title":"Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-12","conditions":"Influenza","enrollment":168},{"nctId":"NCT00971425","phase":"PHASE3","title":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":145},{"nctId":"NCT00979407","phase":"PHASE3","title":"Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":"Influenza","enrollment":336},{"nctId":"NCT00964158","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":210},{"nctId":"NCT00996853","phase":"","title":"Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-31","conditions":"Influenza","enrollment":9206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Influenza vaccine GSK2340272A","genericName":"Influenza vaccine GSK2340272A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2340272A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}